Definitive Contract 75N93018C00043
Award Date
9/10/18
Potential Completion Date
9/29/24
Potential Value
$7.1M
Federal Agency
National Institute of Allergy and Infectious Diseases
Ultimate Awardee
University System Of Maryland
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
Baltimore, MD 21201, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
17
Legislative Mandate
Service Contract Act
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $29,057,109.85 definitive federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to the University of Maryland, Baltimore (UMB) for biomedical research and development. The contract has no set-aside designation. UMB, a major public research university, is the prime contractor and frequently receives federal contracts and grants for its expertise in areas such as medicine, nursing,...
This is a $7,143,498.00 firm fixed-price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to the University of Maryland, Baltimore (UMB) with a completion date of September 29, 2028. The contract does not have a set-aside designation. The award involves the development of an adjuvant, the TLR4 ligand BECC470S, which is a key component in vaccine formulations. UMB is the prime contractor, with the University of Missouri System and the Washington...
This is a $11,109,751.80 Firm Fixed Price contract awarded by the National Institutes of Health (NIH) to the University of Maryland, Baltimore (UMB) to provide support for the Office of AIDS Research Initiative research grant activities. The contract has a period of performance through September 27, 2027 and was awarded on September 28, 2022. UMB, a prominent public research university, will be the prime contractor delivering these services without any set-aside designation. The University...
This federal contract award to the University of Maryland, Baltimore (UMB) was made by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for Vaccine Treatment and Evaluation Units (VTEU). The $910,006.01 contract is a delivery order under the VTEU indefinite delivery vehicle (IDV), which allows NIAID to order various medical research and clinical trial services from UMB as needed. The contract has no set-aside designation. As...
This is a $3,603,949.00 delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to the University of Maryland, Baltimore (UMB) under the Vaccine and Treatment Evaluation Units (VTEU) Indefinite Delivery Vehicle (IDV). The contract supports vaccine and treatment evaluation activities, which is a major program of NIAID. There was no set-aside designation for this award. UMB, the prime contractor, is a leading public research university that...
This is a federal contract award to the University of Maryland, Baltimore (UMB) under the Vaccine and Treatment Evaluation Units (VTEU) contract vehicle, which is administered by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH). The $1,417,081.00 contract is a delivery order for biomedical research and clinical services related to VTEU task order 13-0013.D1.0025-22. UMB, a major public research university, has extensive...
This federal contract award, valued at $669,734.24, was issued by the Food and Drug Administration (FDA) to the University of Maryland, Baltimore (UMB) to provide NONDESTRUCTIVE ANALYTICS FOR VACCINES. The contract is a definitive, firm fixed-price agreement, with a period of performance through March 29, 2024. UMB, the prime contractor, is a major public research university and the founding campus of the University System of Maryland (USM). The contract does not have a set-aside designation....
The University of Maryland, Baltimore (UMB) was awarded a $991,159.60 delivery order contract by the National Institute of Allergy and Infectious Diseases, a civilian agency under the Department of Health and Human Services. This award falls under the Vaccine and Treatment Evaluation Units (VTEU) Indefinite Delivery/Indefinite Quantity (IDIQ) contract, which supports vaccine treatment and evaluation research. The contract has no set-aside designation. The award provides funding for UMB to...
The University of Maryland, Baltimore (UMB) has been awarded a $7,594.08 firm fixed price purchase order contract by the National Institute of Allergy and Infectious Diseases (NIAID) for micro-satellite testing and pyro-sequencing services. UMB, a major public research university, frequently receives federal contracts and grants to support its biomedical and clinical research activities. This contract, which is not set aside, is likely part of a larger research initiative at NIAID, the...
This federal contract award was made by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH), to the University of Maryland, Baltimore (UMB) as the prime contractor. The $2,752,906.46 contract is for Vaccine Treatment and Evaluation Units (VTEU), a major NIAID program that supports clinical trials and medical research on vaccines and treatments for infectious diseases. The contract is a delivery order under the larger VTEU...